Ortho Biotech to Submit Request for Reconsideration Regarding ESA Coverage Policy

Ortho Biotech Products, L.P., the company that markets Procrit (Epoetin alfa), will formally request that the Centers for Medicare and Medicaid Services (CMS) reconsider its final National Coverage Determination (NCD) for erythropoiesis-stimulating agents (ESAs).
PR Newswire